March 21, 2024

The U.S. Food and Drug Administration (FDA) published a paper March 15, to update the public about intra-agency activities to oversee artificial intelligence (AI)-enabled healthcare technologies. The paper summarizes priorities shared across the biologics, drugs and medical devices domains of FDA jurisdiction.

Four general focus areas are discussed: fostering collaboration with stakeholders; developing appropriate regulatory approaches; promoting development of standards and best practices; and supporting research on performance evaluation. Moving forward, the FDA intends to evolve its own regulatory approaches with the continued progression of AI tools.

For more information about various American College of Radiology®(ACR®) AI-specific initiatives, visit the ACR Data Science Institute®. For more information about FDA oversight and digital health policy, contact Michael Peters, ACR Senior Government Affairs Director.


Related ACR News

  • AI Effect on Clinical Practice

    The 2025 SIIM-ACR Data Science Summit brought together leaders in radiology, informatics and healthcare artificial intelligence to explore how AI is reshaping clinical practice.

    Read more
  • Scope of Practice Expansion Bills Become Law in Oklahoma

    Two harmful scope of practice expansion bills in Oklahoma, House Bill (HB) 2298 and HB 2584, recently became law after the state legislature voted to override Gov. Kevin Stitt’s (R) executive decision to veto the bills.

    Read more
  • ACR Advocacy for Members Continues in No Surprises Act Case

    The American College of Radiology® (ACR®) continues its advocacy in the surprise patient billing arena.

    Read more